@LeonLevy: "CSL moving into gene therapy tells you the core business is under threat."
I'll bite seeing as I have nothing better to do at 5am odd. It doesn't tell me that, it tells me it's part of the fruits of spending over one billion a year on R&D (A$1.4 billion this year) so it doesn't have to rely on what you call it's core business. One area is gene therapy, there are plenty of others, CSL is not a one trick pony
Have a read of this: https://www.copyright link/companies/healthcare-and-fitness/csl-enters-ranks-of-world-s-biggest-biotechs-20200114-p53rbv
"For now... it has a strong pipeline coming through which should underpin investor confidence for the medium term.
The company has projects underway targeting a diverse array of conditions. These range from a gene therapy treatment for sickle cell anaemia to subarachnoid haemorrhage (bleeding in the brain following the rupture of an aneurysm) and prevention and treatment of graft-versus-host disease.One of the most advanced therapies in the pipeline is its CSL 112 therapy, which is a plasma-derived product it hopes could be used to prevent often deadly secondary heart attacks, which is currently in a phase three trial."
Anyway, as with Altium, which you also had concerns about being expensive, thanks for your input.
The CSL pattern, page-269
-
-
- There are more pages in this discussion • 1,048 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$308.83 |
Change
0.270(0.09%) |
Mkt cap ! $149.0B |
Open | High | Low | Value | Volume |
$307.48 | $309.17 | $306.25 | $32.63M | 105.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 23 | $308.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$308.83 | 62 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 31 | 309.040 |
3 | 46 | 309.030 |
2 | 27 | 309.020 |
2 | 46 | 309.010 |
2 | 53 | 309.000 |
Price($) | Vol. | No. |
---|---|---|
309.050 | 72 | 5 |
309.060 | 65 | 4 |
309.070 | 71 | 3 |
309.080 | 19 | 2 |
309.100 | 14 | 2 |
Last trade - 11.14am 16/07/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online